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PERSPECTIVES ON DRUGS 
Health and social responses  
for methamphetamine users 
There have been recent reports, however, highlighted by 
a 2013 trendspotter study by the EMCDDA, of changes 
and developments in methamphetamine markets in some 
European countries (EMCDDA, 2014c). These reports have 
highlighted a number of distinct regional trends, each with 
their own characteristics and patterns of use, and usually 
linked with changes in production and trafficking of the drug 
(EMCDDA, 2014d).
Methamphetamine is a stimulant drug that affects the central 
nervous system (EMCDDA, 2014a). A range of health-related 
harms are linked to its use and the route of administration, 
including somatic and mental health problems, as well as an 
increased risk of transmission of infectious diseases such as 
hepatitis C virus (HCV) and human immunodeficiency virus 
(HIV) that are associated with injecting. In particular, the range 
of public health concerns linked with methamphetamine use 
make close surveillance of new developments an important 
policy priority. 
I  Methamphetamine use in Europe
Recent reports from both the Czech Republic and Slovakia 
indicate that there has been a spread of pervitin use among 
problem drug users, which is reflected in increases in 
problem drug use estimates and in the number of people 
entering treatment for the first time who report pervitin 
problems (EMCDDA, 2014b). In addition, new pockets 
of methamphetamine use and associated problems 
have been identified in a number of other European 
countries. Germany, for example, reports the emergence of 
Outbreaks of methamphetamine use 
in the United States and South-East 
Asia have presented major and well-
documented public health problems  
(see interactive timeline). In many cases 
in these regions the main form of use has 
been smoking crystal methamphetamine. 
In contrast, European drug markets have 
historically been dominated by the use of 
amphetamine, with methamphetamine 
use in Europe largely confined to the 
Czech Republic and Slovakia (where the 
drug is known as pervitin). 
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methamphetamine sniffing in recreational drug scenes and 
its use among treatment populations in regions bordering 
the Czech Republic. The presence of methamphetamine 
on some northern European markets has been noted 
in recent years (Griffiths et al., 2008). In Norway, for 
example, methamphetamine use appears to be interlinked 
with the older, more established amphetamine market. 
Particular challenges have arisen in Greece (and to a lesser 
extent Cyprus and Turkey) where the smoking of crystal 
methamphetamine (locally known as ‘s(h)is(h)a’) by injecting 
opioid users has been identified by low-threshold services 
and treatment agencies. In a different development, the 
United Kingdom has reported low, but nevertheless worrying, 
patterns of methamphetamine injecting (known as slamming) 
among small populations of men who have sex with men 
(MSM) (EMCDDA, 2014c).
Increasing awareness of these diverse emerging patterns 
of methamphetamine use has served to put the spotlight 
on the range of harms associated with its use, and the 
availability and adequacy of health and social responses. 
Each population, with its unique pattern of use, is likely to 
raise challenges and place new burdens and demands on 
countries’ public health systems. To date, documentation on 
Europe’s responses to methamphetamine problems is scarce. 
Bearing this in mind, this analysis makes a first attempt to 
identify and highlight emerging challenges for policy and 
service provision linked with the various manifestations of 
methamphetamine use that have recently been identified. This 
includes a brief look at the limited international evidence on 
the effectiveness of interventions.
I Varied problems requiring a range of responses 
Although at low levels, methamphetamine is being used by 
diverse groups of drug users in different ways, and this is 
clearly raising a variety of challenges and initial responses 
from service providers. Services currently identified as 
responding to problems include mental health, low-threshold, 
drug treatment, youth and sexual health.
Methamphetamine has long been used by problem drug users 
in both the Czech Republic and Slovakia, with injection as the 
most common route of administration. In the Czech Republic 
mental health care and residential treatment programmes 
applying the therapeutic community model have been at the 
centre of the response (Kalina, 2007). The focus has been 
on client assessment, the use of psychosocial interventions 
and medical treatment, and social reintegration initiatives. 
Services offering information, including harm reduction advice 
to methamphetamine users, are also available. An innovative 
intervention has involved the distribution of empty
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gelatine capsules by some low-threshold services in order 
to encourage users to consume the drug orally rather than 
injecting it (Mravcik et al., 2011). Such measures are designed 
to reduce the injection-related risks of blood-borne viruses 
(HIV, HCV).
Crystal methamphetamine smoking among opioid injectors 
has recently been reported in Greece, in particular among 
marginalised immigrant sub populations in Athens 
(EMCDDA, 2013). Methamphetamine smoking is associated 
with particular problems for users’ health, including 
respiratory damage and dental corrosion. In Greece, both 
low-threshold and mental health care services have been 
involved in responding to the needs of these users. However, 
a combination of restricted service availability and the 
marginalised social status of these users has reportedly 
exacerbated the health problems in this group (EMCDDA, 
2013).
Several northern European countries with established 
patterns of amphetamine use are now also seeing the 
emergence of methamphetamine use among existing 
stimulant users. In Norway, for example, these two drugs 
have been sold interchangeably, with amphetamine users 
unknowingly consuming methamphetamine. Increased use 
of the drug has also been observed among problem drug 
users in Latvia, with more than half of the users in one cohort 
study reporting methamphetamine as their primary drug in 
2010 (EMCDDA, 2014c). In general in these countries, no 
differentiation has been made between treating users of 
amphetamine and methamphetamine, and psychosocial 
intervention is the form of treatment most widely available for 
stimulant users. 
Methamphetamine is also reportedly used by recreational 
drug users, including clubbers, in several countries, such 
as the Czech Republic, Slovakia, Germany and the United 
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Kingdom. Given the age profile of these users, youth services 
have sometimes been involved in delivering responses 
to them. This has included new multidisciplinary services 
being developed specifically for methamphetamine users. In 
London, a specialist clinic treating drug-using clubbers has 
piloted a set of targeted support for users. It provides drug 
and sexual health services and uses a unique funding scheme 
that allows access to services for people who self-refer from 
across the United Kingdom (Kirby and Thornber-Dunwell, 
2013). With a broader target audience in mind, another British 
online service provides drug education to methamphetamine 
users. The public health service ‘Talk to Frank’ presents 
methamphetamine facts, emergency help, harm reduction and 
drug treatment information to users.
Methamphetamine use has emerged in the United Kingdom 
among small urban populations of MSM (Stuart, 2013). Within 
this group, methamphetamine is being injected (known as 
‘slamming’) at parties where users engage in high-risk sexual 
behaviours (multiple partners, no protection). In this context, 
methamphetamine is one of a number of substances used, 
including synthetic cathinones, GBL and Viagra. These users 
face long-established health risks related to injecting drugs, 
in particular the risk of contracting blood-borne viruses. In 
London, there are reports of users presenting at sexual health 
clinics to receive post-exposure prophylaxis (PEP) for HIV after 
attending slamming parties. In some cases, it has been the 
services dealing with sexual health issues and targeting MSM 
clients that have been frontline responders. For example, in 
the United Kingdom a health promotion initiative operated 
by a London lesbian, gay, bisexual, and transgender health 
and well-being charity is targeting methamphetamine users 
(Marshall et al., 2011). It provides drug, alcohol and sexual 
health counselling, social support groups and telephone 
advice to users (Bourne et al., 2014; Stuart, 2013).
I  Evidence for intervention effectiveness
Much of Europe’s drug treatment provision has been 
developed in response to heroin use and related problems, 
and there is limited documentation of approaches addressing 
stimulant problems. Studies examining the health and social 
responses to problems linked with methamphetamine use 
come primarily from the United States and Australia, where 
smoking of crystal methamphetamine predominates. This 
means the transferability of results to European contexts is 
not assured. Presently, there is consistent evidence in support 
of the efficacy of two psychosocial treatment approaches 
for methamphetamine dependence — cognitive behavioural 
approaches and contingency management. Cognitive 
behavioural approaches, in conjunction with pharmacotherapy 
or as a stand-alone intervention, have been shown to increase 
treatment attendance and to reduce methamphetamine use 
and risky sexual behaviour (Lee and Rawson, 2008; McElhiney 
et al., 2009; Reback and Shoptaw, 2011). Similarly, individuals 
who have been assigned to contingency management 
conditions have demonstrated better retention in treatment, 
lower rates of methamphetamine use and longer periods 
of sustained abstinence over the course of their treatment 
experience (Roll et al., 2013).
To date, although there have been a number of efficacy trials 
of potential methamphetamine pharmacotherapies (e.g. 
buproprion, modafinil), all candidate drugs have been shown 
to be no more effective than placebo. Consequently, there 
are no approved medications for treating methamphetamine 
dependence, and pharmacotherapy is recommended as an 
adjunct to psychosocial interventions rather than being a 
primary component of treatment (Brackins et al., 2011; Karila 
et al., 2010; Rajasingham et al., 2012).
I  Terms and definitions 
Acute adverse effects 
Acute methamphetamine intoxication or overdose can 
lead to severe hyperthermia, renal failure and heart attacks 
(Lan et al., 1998). 
As stimulant effects dissipate, users may experience 
drowsiness, reduced ability to concentrate and/or 
impaired judgment and learning (Meredith et al., 2005).
Personality issues and changes commonly experienced 
are low mood, anxiety, depression, irritability, aggression 
(Meredith et al., 2005).
Acute paranoid psychosis (psychotic reaction similar to 
acute paranoid schizophrenia) may develop after single 
or repeated use of methamphetamine; people with 
underlying mental health problems are at greatest risk 
(Chen et al., 2003; Grant et al., 2012).
Chronic adverse effects 
Chronic use changes the brain — tolerance develops, 
leading users to take higher doses.
Smoking methamphetamine can lead to lung complaints 
including pulmonary hypertension or oedema (fluid 
retention) (Thompson, 2008).
The skin and the mouth can be affected — teeth and gums 
decay rapidly due to the acidic nature of the drug and poor 
dental hygiene (known as ‘meth mouth’) (Hamamoto and 
Rhodus, 2009).
Sources: www.talktofrank.com/drug/methamphetamine
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I  Conclusion
While methamphetamine is an established drug in other 
parts of the world and in some European countries, it is now 
emerging in EU Member States where it has not previously 
been recorded. It is being used by different populations 
of drug users, encompassing socially integrated users 
who sniff or inject the drug and marginalised populations 
where methamphetamine is smoked. As such, Europe’s 
current methamphetamine problem has no single face and 
appropriate responses will need to be adapted, developed and 
tailored to the local patterns of use and problems observed. 
This will undoubtedly require service providers to adopt 
flexible referral practices and develop existing services, for 
example tried and tested psychosocial interventions, and to 
build complementary treatments for users. As patterns and 
these new developments in methamphetamine use continue 
to evolve within Europe, it will be important to monitor how 
use of the drug is developing and to continue to shape 
responses towards users’ needs.
Interactive element — methamphetamine global timeline, available on 
the EMCDDA website: emcdda.europa.eu/topics/pods/responses-for-
methamphetamine-users
I  Interactive element
Methamphetamine exists in two optical isomeric forms, 
d and l. Both are psychoactive, having stimulant effects, 
however, the d-form is more potent and longer-lasting than 
the l-form. Illicit methamphetamine in Europe is normally a 
mixture of both d- and l-forms. 
 
D-and l-methamphetamine can come in two physical forms, 
base and salt. The pure base is a clear, colourless volatile 
oil, insoluble in water, which can be easily converted into 
methamphetamine hydrochloride (the most prominent salt 
form). 
 
On the illicit drug market methamphetamine is sold as a 
crystalline solid or powder. The crystalline solid is often 
called ‘ice’ or ‘crystal meth’ due to its appearance. ‘Ice’ is 
suitable for smoking as high-purity methamphetamine 
hydrochloride can be vaporised without thermal 
decomposition. In powder methamphetamine, granules 
of the salt are mixed with other ingredients (e.g. lactose, 
dextrose, caffeine); the proportion of methamphetamine to 
the other ingredients determines the purity. 
Powder methamphetamine found on the illicit drugs 
market is similar to powder amphetamine in many ways, 
including in its purity and appearance, and the two are 
often indistinguishable to both users and dealers. Powder 
methamphetamine tends to be administered in the same 
way as amphetamine powder — either inhaled intra-nasally 
(snorted) or dissolved and injected. 
 
 
 
 
 
Forms of methamphetamine 
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